FLUNIVAC

InFLUenza virus UNIVersal VACcine development program

 Coordinatore ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM 

 Organization address address: 's Gravendijkwal 230
city: ROTTERDAM
postcode: 3015CE

contact info
Titolo: Mr.
Nome: Wim
Cognome: Leep
Email: send email
Telefono: +31 10 7043451
Fax: +31 10 7044760

 Nazionalità Coordinatore Netherlands [NL]
 Totale costo 6˙973˙633 €
 EC contributo 5˙066˙881 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2013-INNOVATION-1
 Funding Scheme CP-FP
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-10-01   -   2017-09-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

 Organization address address: 's Gravendijkwal 230
city: ROTTERDAM
postcode: 3015CE

contact info
Titolo: Mr.
Nome: Wim
Cognome: Leep
Email: send email
Telefono: +31 10 7043451
Fax: +31 10 7044760

NL (ROTTERDAM) coordinator 1˙218˙786.00
2    ARTEMIS ONE HEALTH RESEARCH BV

 Organization address address: JENALAN 18C
city: UTRECHT
postcode: 3584CK

contact info
Titolo: Prof.
Nome: Eric
Cognome: Claassen
Email: send email
Telefono: +31 6 20443098

NL (UTRECHT) participant 918˙211.00
3    Q-BIOLOGICALS NV

 Organization address address: TECHNOLOGIEPARK 4
city: GENT
postcode: 9052

contact info
Titolo: Dr.
Nome: Annie
Cognome: Van Broekhoven
Email: send email
Telefono: +32 475966070

BE (GENT) participant 606˙002.00
4    PROBIOGEN AG

 Organization address address: Goethestrasse 54
city: Berlin
postcode: 13086

contact info
Nome: Andrea
Cognome: Hauptmann
Email: send email
Telefono: +49 30 924006148
Fax: 493092000000

DE (Berlin) participant 586˙050.00
5    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN

 Organization address address: GESCHWISTER SCHOLL PLATZ 1
city: MUENCHEN
postcode: 80539

contact info
Titolo: Prof.
Nome: Gerd
Cognome: Sutter
Email: send email
Telefono: +4989 21802514
Fax: +4989 218016576

DE (MUENCHEN) participant 526˙360.00
6    VIB

 Organization address address: Rijvisschestraat 120
city: ZWIJNAARDE - GENT
postcode: 9052

contact info
Nome: Rik
Cognome: Audenaert
Email: send email
Telefono: 3292446611
Fax: 3292446610

BE (ZWIJNAARDE - GENT) participant 520˙260.00
7    Aimm Therapeutics BV

 Organization address address: Meibergdreef 45
city: Amsterdam
postcode: 1105BA

contact info
Titolo: Dr.
Nome: Willem
Cognome: Van Oort
Email: send email
Telefono: +31 20 5662145
Fax: +31 20 5669081

NL (Amsterdam) participant 394˙662.00
8    NOVAVAX AB

 Organization address address: KUNGSGATAN 109
city: UPPSALA
postcode: 753 18

contact info
Titolo: Mr.
Nome: Erik
Cognome: Bergman
Email: send email
Telefono: +4618 161729
Fax: +4618 161701

SE (UPPSALA) participant 296˙550.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

regions    conserved    vaccine    virus    fail    protection    immune    proteins    mvas    immunity    antibody    natural    lasting    infection    viruses    protective    tested    broad    mva    cell    influenza    induce    responses    pb       induced    recombinant   

 Obiettivo del progetto (Objective)

Effectively protecting the general population from seasonal and pandemic influenza has proven to be a challenge, since influenza viruses continue to escape from and evade immunity. Current influenza vaccines fail to provide long-lasting and broad protection against multiple strains of influenza. For the development of a universal influenza vaccine, we have to “do better than Nature”, since even natural influenza virus infections fail to induce broad protective immunity. To induce broad-protective and long-lasting immunity an influenza vaccine should therefore be directed to conserved viral proteins or regions thereof that are insufficiently exposed upon natural infection. FLUNIVAC is a SME-targeted collaborative research project that aims to develop a candidate influenza vaccine based on recombinant MVA expressing both antibody and T-cell response-inducing proteins, ready to commence Phase I clinical trials within 4 years. We will generate recombinant MVAs that express nine conserved (regions of) influenza A virus proteins (surface proteins HA, NA, M2e, internal proteins M1, NP, NS1, and the polymerase proteins PB1, PB2, PA). These proteins are targets for both antibody and T-cell mediated immune responses, since the induction of solely one of both affords only modest protection against infection with influenza viruses of heterologous subtypes. These recombinant MVAs will be tested for their capacity to induce the desired broad-protective immune response individually and in selected combinations in vivo. In parallel, MVA-induced immune responses will be tested for their longevity and boostability as compared with those induced with adjuvanated vaccine preparations. Furthermore, the MVA platform will be optimized in terms of: i) kinetics and extent of protein-expression of the MVA vector to optimally activate the respective arms of the immune system; ii) a viable unified production process, independent of embryonated chicken eggs, will be designed and implemented.

Altri progetti dello stesso programma (FP7-HEALTH)

NEUROSTEMCELL (2008)

European Consortium for Stem Cell Therapy for Neurodegenerative Diseases

Read More  

AIPGENE (2011)

Augmenting PBGD expression in the liver as a Novel Gene therapy for Acute Intermittent Porphyria

Read More  

PDE4NPD (2014)

Parasite-specific cyclic nucleotide phosphodiesterase inhibitors to target Neglected Parasitic Diseases

Read More